ResMed Support for Investigator-Initiated Research

ResMed changes lives with award-winning medical devices and cutting-edge cloud-based software applications that diagnose, treat and manage sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD) and other chronic respiratory diseases. ResMed is a global leader in connected care, with millions of patients remotely monitored every day. Our team is committed to creating the world’s best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 100 countries.

As part of our commitment to deliver innovative therapies to patients across the globe, ResMed believes in the need to support ethical, independent clinical research, conducted by qualified third-party investigators. Investigator Initiated Research (IIR) serves as an important complement to ResMed-sponsored research, to help better understand the benefits and risks of our therapies, as well as to explore new opportunities to address unmet medical needs. Such clinical research must be aimed at addressing meaningful scientific and/or clinical objectives, supported by valid study designs in which the safety, welfare and privacy rights of patients are of paramount importance. 

Like many other health care-focused companies, ResMed supports the funding of Investigator Initiated Research (IIR) through a well-defined process with robust governance measures. Preference will be given to programs that align with the ResMed mission of advancing innovative technologies in sleep and respiratory medicine. Support is typically provided in the manner of funding and/or devices, depending on the type of research. 

Key areas of interest include:

  • Optimisation of clinical pathways to improve accessibility and efficiency in the diagnosis and treatment of sleep apnea. 
  • Innovative strategies to enhance initial compliance and long-term adherence to PAP therapy, especially through use of telemedicine.
  • Evidence to show the economic value of treating sleep apnea and COPD. 
  • Association of clinical outcomes and quality of life with the use of portable oxygen concentrators (POCs).
  • Contribution to scientific knowledge and patient pathways for the use of non-invasive ventilation. 
  • New insights into utilising clinical data to improve patients’ lives; for example, through reducing hospital admissions, reducing healthcare costs, enabling meaningful prediction of exacerbations, increasing quality of life, patient engagement.

Submitting an IIR proposal

ResMed accepts IIR proposals from qualified potential investigators. Review of IIR proposals occur quarterly at ResMed. 2019 deadlines for all IIR Proposal submissions will be: January 20th, April 25th, July 13th, October 18th. The ResMed Clinical Review Board conducts the review process and decisions are based upon medical and scientific merit as well as the available resources and research priorities. The Clinical Review Board will provide a decision letter to each Investigator within 2 weeks of each submission deadline. While all requests will be reviewed, ResMed makes no promises that it will approve a request. 

Source